---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209112"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:44:02.587035+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma regains Nasdaq minimum bid price compliance

## Summary
- Received Nasdaq notice on Aug 9, 2023, confirming compliance with Bid Price Rule 5550(a)(2).
- Compliance achieved after closing price at $1.00/share or higher for 10 consecutive trading days.
- Original deficiency notice was received on Sep 6, 2022, for bid price below $1.00 for 30 days.
- Nasdaq has closed the matter; no further action required from the company.

## SEC filing metadata
- accession: 0001193125-23-209112
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523209112/0001193125-23-209112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523209112/d544334d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209112
- JSON: https://secwatch.observer/filing/0001193125-23-209112.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209112.txt

## Key facts
- Listing & Compliance Notices
  Benitec Biopharma Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 9, 2023, the Company received written notice from the Listing Qualifications Department of Nasdaq informing the Company that it has regained compliance with the Bid Price Rule based on the closing price of the Company’s common stock having been at $1.00 per share or greater for 10 consecutive trading days and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: August 10, 2023 /s/ Jerel
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523209112/0001193125-23-209112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.